Eli Lilly’s weight loss drug Zepbound led to significantly greater weight loss than Novo Nordisk’s Wegovy in a 72-week, head-to-head clinical trial, according to findings published in The New England Journal of Medicine and presented at the European Congress on Obesity.
The trial included adults with obesity or those who were overweight and had at least one related health condition. On average, patients taking Zepbound lost 20.2% of their body weight, compared to 13.7% for those on Wegovy, according to a May 11 news release from Eli Lilly.
Nearly twice as many patients on Zepbound lost at least 25% of their body weight as those on Wegovy. Additionally, 81.6% of Zepbound patients lost 10% or more, versus 60.5% of those on Wegovy.
According to Bloomberg, the 47% greater weight loss with Zepbound included around two more inches off patients’ waists, a difference researchers told the news outlet can impact blood pressure and other health measures.
